D.E. Shaw & Co’s Adverum Biotechnologies ADVM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-17,153
Closed -$77.7K 4564
2025
Q3
$77.7K Sell
17,153
-9,599
-36% -$28.3K ﹤0.01% 4378
2025
Q2
$57.5K Sell
26,752
-192
-0.7% -$537 ﹤0.01% 4165
2025
Q1
$118K Sell
26,944
-20,670
-43% -$93.2K ﹤0.01% 4001
2024
Q4
$222K Buy
+47,614
New +$320K ﹤0.01% 4038
2020
Q4
Sell
-2,424
Closed -$250K 3874
2020
Q3
$250K Buy
+2,424
New +$363K ﹤0.01% 3531
2020
Q2
Sell
-6,052
Closed -$592K 3956
2020
Q1
$592K Sell
6,052
-13,064
-68% -$1.52M ﹤0.01% 3117
2019
Q4
$2.2M Sell
19,116
-3,827
-17% -$337K ﹤0.01% 2384
2019
Q3
$1.25M Buy
22,943
+9,632
+72% +$1.09M ﹤0.01% 2702
2019
Q2
$1.58M Buy
13,311
+10,721
+414% +$887K ﹤0.01% 2398
2019
Q1
$136K Sell
2,590
-70
-3% -$2.83K ﹤0.01% 3449
2018
Q4
$84K Sell
2,660
-3,925
-60% -$160K ﹤0.01% 3654
2018
Q3
$398K Sell
6,585
-2,160
-25% -$121K ﹤0.01% 3230
2018
Q2
$463K Buy
8,745
+5,473
+167% +$329K ﹤0.01% 3160
2018
Q1
$190K Buy
+3,272
New +$204K ﹤0.01% 3337
2017
Q2
Sell
-1,832
Closed -$49K 3339
2017
Q1
$49K Buy
+1,832
New +$52.1K ﹤0.01% 3229
2016
Q4
Sell
-1,415
Closed -$58K 3408
2016
Q3
$58K Sell
1,415
-7,706
-84% -$292K ﹤0.01% 3317
2016
Q2
$288K Buy
+9,121
New +$412K ﹤0.01% 3033
2015
Q3
Sell
-1,004
Closed -$163K 3698
2015
Q2
$163K Buy
+1,004
New +$339K ﹤0.01% 3610
2014
Q4
Sell
-595
Closed -$203K 3965
2014
Q3
$203K Buy
+595
New +$177K ﹤0.01% 3884

D.E. Shaw & Co's ADVM Position: Q4 2025 in Review

D.E. Shaw & Co sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 17,153 shares — an estimated $77.7K sold.

D.E. Shaw & Co first reported a position in ADVM in Q3 2014 and held it in 19 quarters. The position peaked at $2.2M in Q4 2019. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • D.E. Shaw & Co reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 17,153 Adverum Biotechnologies shares in Q4 2025, an estimated $77.7K.
  • D.E. Shaw & Co first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 19 quarters.
  • D.E. Shaw & Co's Adverum Biotechnologies position peaked at $2.2M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.